Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IRS Rule On Flex-Spending Accounts A Boon For Chronic-Use OTCs, Switches

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough's Claritin and Procter & Gamble's Prilosec OTC are likely to be major beneficiaries of an IRS ruling that nonprescription drugs can be covered by employee health flexible spending arrangements
Advertisement

Related Content

Visa, Finpago Payment Systems Help Health Account Customers Buy OTCs
Supplement Coverage Under HSAs, FSAs Advanced By “Tax Parity” Coalition
Blues HSA Plans To Go Nationwide As Medicare Drug Benefit Kicks In
McNeil, Debit Card Maker Partner In Flex Spending Account Campaign
Drugstore.com gets more Flexible
FSA bill rollover to Senate
OTC Tax Deductibility Is Capital Issue At CHPA Conference In D.C.
OTCs Would Be Tax Deductible Under House Bill; Supplement Status Unclear
FSAs and drugstore.com
AstraZeneca Sees Prilosec OTC As “Neutral To Beneficial” For Nexium Sales

Topics

Advertisement
UsernamePublicRestriction

Register

PS095902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel